You are here
Mattek Corporation
UEI: Q1V1JV6GJW77
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Organotypic Culture Models (OCM) developed from experimental animals for Chemical Toxicity Screening.
Amount: $252,129.00The demand for herbicides, insecticides, and fungicides will lead to increased production of new chemicals by the agrochemical industry which may pose significant risk to human health. The objective o ...
SBIRPhase I2020Department of Health and Human Services National Institutes of Health -
ELECTROSPUN BIODEGRADABLE MEMBRANE INSERTS (POP:7/27/2020 TO 04/26/2021)
Amount: $225,000.00The need for more complex 3D tissue models by pharmaceutical and academic researchers is increasing. A key factor for certain tissue models is a scaffold that promotes structural integrity, cell ancho ...
SBIRPhase I2020Department of Health and Human Services National Institutes of Health -
Novel Approach for Characterizing Exposure and Response to Engineered Nanomaterials in the Gut
Amount: $225,000.00Consumer safety concerns are mounting as engineered nanoparticlesENPsare increasingly being incorporated into consumable productssuch as fooddrugsand personal care productsWhile toxicological effects ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Organotypic Rat Tissue Models for Translational Toxicity Assessments
Amount: $223,936.00AbstractThe goal of the current Phase I SBIR project is to develop commercially scalable and reproducible in vitrodimensional organotypic models of rat tissues including airwaybronchial and alveolarin ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Validation of an In Vitro Human Airway Model for Regulatory Toxicity Testing
Amount: $1,203,353.00Results of Phase II research indicate that formal validation of the EpiAirwayin vitro human bronchial tissue model for predicting toxicity of inhaled chemicals is an attainable goalThe proposed Phase ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
An In Vitro Human Small Intestine Tissue Model for Drug Permeation Studies
Amount: $1,329,781.00DESCRIPTIONprovided by applicantApproximatelyof currently marketed drugs are orally administered formulations whose clinical efficacy critically depends on the absorption from the small intestineSMIHo ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
An In Vitro Human Small Intestine Tissue Model for Drug Permeation Studies
Amount: $218,331.00DESCRIPTION (provided by applicant): The perioral route for drug administration remains the most convenient way of clinical therapy and is preferred by patients, however, good bioavailability is a nec ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Genetically modified tissue engineered in vitro human models
Amount: $966,454.00DESCRIPTION (provided by applicant): The goal of the current proposal is to apply state-of-the-art gene modification technology, including lentiviral delivery systems and RNA interference (RNAi) techn ...
SBIRPhase II2012Department of Health and Human Services National Institutes of Health -
Validation of an In Vitro Human Airway Model
Amount: $835,982.00DESCRIPTION (provided by applicant): Hazard assessment, including evaluation of acute inhalation toxicity potential, is a mandatory international regulatory requirement for chemicals utilized in inter ...
SBIRPhase II2011Department of Health and Human Services National Institutes of Health -
Validation of Human Vaginal Tissue Assay for Endocrine Disruptors
Amount: $993,515.00DESCRIPTION (provided by applicant): Environmental or occupational exposure to a broad variety of chemical agents can alter normal endocrine function. The effects of these endocrine disruptors (ED) ...
SBIRPhase II2011Department of Health and Human Services National Institutes of Health
